Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivatuzumab mertansine in CD44v6+ breast cancer
NCT02254031Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2003
- Primary completion
- Jan 2005
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of bivatuzumab mertansine in breast cancer, sponsored by Boehringer Ingelheim. Primary endpoint: Maximum Tolerated Dose up to 6 months. Started Jul 2003; status: terminated.
02
Drugs
bivatuzumab mertansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02254031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254031.